A Study in Elderly Chinese Subjects With Underlying Diseases
Study Details
Study Description
Brief Summary
Evaluate the safety and tolerability of oral JT001 tablets in elderly subjects with underlying diseases.
Evaluate the pharmacokinetic characteristics of JT001 tablets orally administered to elderly subjects with underlying diseases.
Explore the drug drug interactions between JT001 tablets and some drugs in elderly subjects with underlying diseases who have been orally administered multiple times.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
The open-label, single-center phase I study to evaluate the safety, tolerability, and pharmacokinetics of JT001 single-and multiple-dose administered orally in elderly subjects with underlying diseases.Approximately 16 to 18 elderly subjects will be enrolled aging beyound 60 years.
All subjects received JT001, oral administration after meals, D1: 0.6g, twice a day; D2-D5:
0.3g, twice a day; D6: 0.3g, administered once in the morning.Blood samples will be collected at times sufficient to adequately define the pharmacokinetics of JT001 active metabolite(116N-1) in elderly groups.The steady-state trough concentration of therapeutic drug monitoring (TDM) for the basic medication of the subjects will be collected as well.
Subjects will be admitted to the phase I clinical trial ward 2 days before administration (D-2) and will not be allowed to leave until all examinations and assessments are completed on day 8. Telephone follow-up will be performed on day 12 (±1 day).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Elderly subjects elderly subjects with underlying diseases. |
Drug: Deuremidevir Hydrobromide Tablets
Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The severity of SAE [From Day 1(first dose) to Day12]
The severity of SAE
- The Number of participants with SAE [From Day 1(first dose) to Day12]
The Number of participants with SAE
- The severity ofclinical symptoms abnormalities(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness） [From Day 1(first dose) to Day12]
The severity ofclinical symptoms abnormalities(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness）
- The Number of participantswith abnormal clinical symptoms(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness） [From Day 1(first dose) to Day12]
The Number of participantswith abnormal clinical symptoms(e.g.,Dizziness, headache, nausea, abdominal pain, fatigue, drowsiness）
- The severity of vital signs abnormalities [From Day 1(first dose) to Day12]
The severity of Pulse abnormalities
- The Number of participantswith abnormal vital signs [From Day 1(first dose) to Day12]
The Number of participantswith abnormal Pulse
- The severity of vital signs abnormalities [From Day 1(first dose) to Day12]
The severity of blood pressure abnormalities
- The Number of participantswith abnormal vital signs [From Day 1(first dose) to Day12]
The Number of participantswith abnormal blood pressure
- The severity of vital signs abnormalities [From Day 1(first dose) to Day12]
The severity of respiration abnormalities
- The Number of participantswith abnormal vital signs [From Day 1(first dose) to Day12]
The Number of participantswith abnormal respiration
- The severity of vital signs abnormalities [From Day 1(first dose) to Day12]
The severity of body temperature abnormalities
- The Number of participantswith abnormal vital signs [From Day 1(first dose) to Day12]
The Number of participantswith abnormal body temperature
- The severity of vital signs abnormalities [From Day 1(first dose) to Day12]
The severity of abnormal physical examinations findings
- The Number of participantswith abnormal physical examinations findings [From Day 1(first dose) to Day12]
The Number of participantswith abnormal physical examinations findings
- The severity of abnormal laboratory tests results [From Day 1(first dose) to Day12]
The severity of abnormal laboratory tests results
- The Number of participantswith abnormal laboratory tests results [From Day 1(first dose) to Day12]
The Number of participantswith abnormal laboratory tests results
- The severity of electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The severity of Heart rate abnormalities
- The Number of participants with electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The Number of participants with Heart rate abnormalities
- The severity of electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The severity of PR interval abnormalities
- The Number of participants with electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The Number of participants with PR interval abnormalities
- The severity of electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The severity of QRS interval abnormalities
- The Number of participants with electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The Number of participants with QRS interval abnormalities
- The severity of electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The severity of QT interval abnormalities
- The Number of participants with electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The Number of participants with QT interval abnormalities
- The severity of electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The severity of QTcF abnormalities
- The Number of participants with electrocardiogram (ECG) abnormalities [From Day 1(first dose) to Day7]
The Number of participants with QTcF abnormalities
Secondary Outcome Measures
- The Cmax of the main metabolite 116-N1 of JT001; [Day 1/Day 5 and Day 6 after first dose]
area under curve from time zero to infinity
- The AUC0-t of the main metabolite 116-N1 of JT001; [Day 1/Day 5 and Day 6 after first dose]
area under curve from time zero to infinity
- The AUC0-inf of the main metabolite 116-N1 of JT001; [Day 1/Day 5 and Day 6 after first dose]
area under curve from time zero to infinity
Other Outcome Measures
- The steady-state trough concentration of therapeutic drug monitoring (TDM) for the basic medication of the subjects. [Day 2 and Day 1before first dose and Day 6/Day 7/Day 8 after first dose]
The steady-state trough concentration of therapeutic drug monitoring (TDM)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 60 years old, regardless of gender;
-
Weight: Male ≥ 50 kg, female ≥ 45 kg; Body mass index (BMI) within the range of 18-30 kg/m2 (including 18 and 30);
-
Subjects suffer from chronic basic diseases and have stable disease control (such as well controlled hypertension, hyperlipidemia, diabetes, etc.);
-
At least 2 weeks before enrollment, the treatment plan for chronic underlying diseases of the subjects has not been adjusted, and the usage, dosage, and duration of the treatment drugs remain unchanged;
-
During the study period, the subjects were willing to discontinue non essential concomitant medications or health products (excluding essential treatment drugs for chronic underlying diseases of the subjects, and the specific drugs and health products were determined by the researchers and specialist doctors in consultation);
-
The results of vital signs, physical examinations, routine laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function, etc.), 12-lead electrocardiogram, chest X-ray, abdominal ultrasound, etc. are normal or abnormal, but the researchers determine that they are related to age and chronic diseases. After enrollment, the safety risk of the subjects is low and does not affect the study observation indicators;
-
Those who understand the research procedures and methods, voluntarily participate in this study, and sign an informed consent form in writing.
Exclusion Criteria:
-
Individuals with a known history of allergies, allergic diseases, or allergic constitutions to the research formulation, any of its components, or related preparations;
-
Any surgical situation or condition that may significantly affect the absorption, distribution, metabolism, and excretion of drugs, or any surgical situation or condition that may pose a hazard to the participants in the study, such as a history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), a history of gastroenteritis, gastrointestinal ulcers, gastrointestinal bleeding, history of malignant tumors, etc. (excluding cholecystectomy);
-
Those who have experienced the following conditions within 3 months prior to the administration of the study drug: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, congestive heart failure, severe arrhythmia, cerebrovascular accidents, including transient ischemic attacks;
-
Individuals who have experienced blood loss of ≥ 400 mL within the first 3 months of enrollment;
-
Individuals who have participated in clinical research on other drugs or medical devices within the first 3 months of being selected;
-
Drink alcohol at least twice a day or more than 14 times a week within 6 months before selection, or indulge in excessive drinking (one drink is defined as 125 mL of wine, 220 mL of beer or 50 mL of Baijiu; excessive drinking is defined as five or more drinks within about 2 hours);
-
Individuals with a history of drug use or positive drug abuse screening;
-
Those who smoke more than 10 cigarettes per day within the first 6 months of enrollment;
-
Positive individuals for hepatitis B surface antigen (HBsAg), HCV antibody, Treponema pallidum antibody, and HIV antibody;
-
Researchers believe that there are other factors that are not suitable for participating in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Xuhui Central Hospital | Shanghai | Shanghai | China | 200031 |
Sponsors and Collaborators
- Shanghai Vinnerna Biosciences Co., Ltd.
- Sponsor GmbH
Investigators
- Study Director: Huiyu Lan, Project Director, Shanghai Vinnerna Biosciences Co., Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JT001-017-I